Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85.25 USD | +0.22% | -1.37% | +11.80% |
01/05 | Edwards Lifesciences Insider Sold Shares Worth $1,212,687, According to a Recent SEC Filing | MT |
30/04 | Edwards Lifesciences Insider Sold Shares Worth $622,062, According to a Recent SEC Filing | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.67 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.80% | 51.26B | B+ | ||
+7.84% | 218B | B | ||
+7.35% | 183B | B- | ||
+13.04% | 134B | B- | ||
+26.03% | 106B | A- | ||
-1.33% | 61.12B | A- | ||
+4.81% | 50.89B | B+ | ||
+0.30% | 40.3B | A | ||
+2.78% | 35.53B | - | ||
+26.14% | 32.05B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EW Stock
- Ratings Edwards Lifesciences Corporation